This page shows the latest Comirnaty news and features for those working in and with pharma, biotech and healthcare.
The approval comes after the vaccine, known as Comirnaty Omicron XBB.1.5, met the MHRA’s standards of safety, quality and effectiveness against the currently circulating Omicron XBB.1.5 ... only showed 64% of detectable antibodies in people, compared
However, ABNCoV2’s ability to neutralise antibodies against the circulating Omicron variant, XBB.1.5, was significantly lower than the original version of Pfizer and BioNTech’s Comirnaty. ... The data showed that 64% of people had detectable
Pfizer and BioNTech’s Comirnaty XXB.1.5-adapted COVID-19 vaccine has been approved by the European Commission (EC) for adults, children and infants aged over six months. ... The Comirnaty XBB.1.5-adapted COVID-19 vaccine is currently the third
older. The Committee for Medicinal Products for Human Use (CHMP) has specifically recommended marketing authorisation for a single dose of the vaccine, known as Comirnaty Omicron XBB.1.5, in eligible
The regulator’s decision was based on data from a study of 765 adults who received primary vaccination with two doses of the Comirnaty COVID-19 vaccine and then a booster ... dose of either Bimervax or Comirnaty.
In December 2022, the companies announced that approximately two billion doses of Comirnaty were invoiced globally that year, including around 550 million doses of the Original/Omicron BA.4-5-adapted
More from news
Approximately 10 fully matching, plus 29 partially matching documents found.
No results were found
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...